These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

786 related articles for article (PubMed ID: 32783489)

  • 1. Pathological and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed by Cystectomy with or without Neoadjuvant Chemotherapy.
    Hajiran A; Azizi M; Aydin AM; Zemp L; Peyton CC; Dhillon J; Nealon S; Reich RR; Cao B; Li R; Manley BJ; Sexton WJ; Gilbert SM
    J Urol; 2021 Jan; 205(1):100-108. PubMed ID: 32783489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer.
    Chakiryan NH; Jiang DD; Gillis KA; Green E; Hajiran A; Hugar L; Zemp L; Zhang J; Jain R; Chahoud J; Poch M; Manley BJ; Li R; Sexton W; Gilbert SM
    J Urol; 2021 Oct; 206(4):924-932. PubMed ID: 34032503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?
    Berg S; D'Andrea D; Vetterlein MW; Cole AP; Fletcher SA; Krimphove MJ; Marchese M; Lipsitz SR; Sonpavde G; Noldus J; Shariat SF; Kibel AS; Trinh QD; Mossanen M
    Cancer; 2019 May; 125(9):1449-1458. PubMed ID: 30620387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
    Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
    Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Outcomes After Neoadjuvant Chemotherapy and Radical Cystectomy in the Presence of Urothelial Carcinoma of the Bladder With Squamous or Glandular Differentiation.
    Zargar-Shoshtari K; Sverrisson EF; Sharma P; Gupta S; Poch MA; Pow-Sang JM; Spiess PE; Sexton WJ
    Clin Genitourin Cancer; 2016 Feb; 14(1):82-8. PubMed ID: 26411593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy.
    Zargar H; Shah JB; van Rhijn BW; Daneshmand S; Bivalacqua TJ; Spiess PE; Black PC; Kassouf W;
    J Urol; 2018 Jun; 199(6):1452-1458. PubMed ID: 29329894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology.
    Vetterlein MW; Wankowicz SAM; Seisen T; Lander R; Löppenberg B; Chun FK; Menon M; Sun M; Barletta JA; Choueiri TK; Bellmunt J; Trinh QD; Preston MA
    Cancer; 2017 Nov; 123(22):4346-4355. PubMed ID: 28743155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The prognostic value of adjuvant and neoadjuvant chemotherapy in total cystectomy for locally advanced bladder cancer].
    Habuchi T; Kakehi Y; Terachi T; Ogawa O; Yoshida O
    Nihon Hinyokika Gakkai Zasshi; 1999 Oct; 90(10):809-17. PubMed ID: 10565159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemotherapy in the treatment of muscle invasive bladder cancer with mixed histology.
    Lin J; Whalen M; Holder D; Hruby G; Decastro GJ; McKiernan J
    Can J Urol; 2013 Apr; 20(2):6690-5. PubMed ID: 23587508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer.
    Aydin AM; Cheriyan SK; Reich R; Hajiran A; Peyton CC; Zemp L; Yu A; Li R; Poch MA; Spiess PE; Jain R; Zhang J; Sexton WJ; Gilbert SM
    Urol Oncol; 2022 Oct; 40(10):453.e19-453.e26. PubMed ID: 35811208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognosis of early stage small cell bladder cancer is not always dismal.
    Lim JH; Sundar S
    ESMO Open; 2019; 4(6):e000559. PubMed ID: 31798978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative chemotherapy for prostatic stromal invasive urothelial bladder cancer: comparison of oncological outcomes of male patients with cT4a disease undergoing radical cystectomy with or without preoperative chemotherapy.
    Chen J; Miranda G; Cai J; Daneshmand S; Djaladat H
    Scand J Urol; 2019; 53(2-3):123-128. PubMed ID: 31081431
    [No Abstract]   [Full Text] [Related]  

  • 13. Increasing Rates of Perioperative Chemotherapy are Associated With Improved Survival in Men With Urothelial Bladder Cancer With Prostatic Stromal Invasion.
    Rosiello G; Knipper S; Palumbo C; Pecoraro A; Luzzago S; Deuker M; Tian Z; Gandaglia G; Gallina A; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
    Clin Genitourin Cancer; 2020 Feb; 18(1):35-44.e1. PubMed ID: 31711842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management Trends and Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: Evolution of the University of Southern California Experience over 3,347 Cases.
    Mitra AP; Cai J; Miranda G; Bhanvadia S; Quinn DI; Schuckman AK; Djaladat H; Daneshmand S
    J Urol; 2022 Feb; 207(2):302-313. PubMed ID: 34994657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer.
    Hermans TJN; Voskuilen CS; Deelen M; Mertens LS; Horenblas S; Meijer RP; Boormans JL; Aben KK; van der Heijden MS; Pos FJ; de Wit R; Beerepoot LV; Verhoeven RHA; van Rhijn BWG
    Int J Cancer; 2019 Mar; 144(6):1453-1459. PubMed ID: 30155893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective analysis of the efficacy of two cycles of M-VAC neoadjuvant chemotherapy followed by radical cystectomy for muscle-invasive bladder cancer.
    Kitagawa Y; Izumi K; Miwa S; Kadono Y; Konaka H; Mizokami A; Namiki M
    Anticancer Res; 2013 Oct; 33(10):4497-503. PubMed ID: 24123021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of Transurethral Resection plus Systemic Chemotherapy as Definitive Treatment for Muscle Invasive Bladder Cancer in Population Level Data.
    Audenet F; Waingankar N; Ferket BS; Niglio SA; Marqueen KE; Sfakianos JP; Galsky MD
    J Urol; 2018 Nov; 200(5):996-1004. PubMed ID: 29879397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contemporary use and survival after perioperative systemic chemotherapy in patients with locally advanced non-metastatic urothelial carcinoma of the bladder treated with radical cystectomy.
    Mazzone E; Nazzani S; Knipper S; Tian Z; Preisser F; Gallina A; Soulières D; Tilki D; Montorsi F; Shariat SF; Saad F; Briganti A; Wisnivesky J; Karakiewicz PI
    Eur J Surg Oncol; 2019 Jul; 45(7):1253-1259. PubMed ID: 30755341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of Plasmacytoid Variant Histology on the Survival of Patients with Urothelial Carcinoma of Bladder after Radical Cystectomy.
    Li Q; Assel M; Benfante NE; Pietzak EJ; Herr HW; Donat M; Cha EK; Donahue TF; Bochner BH; Dalbagni G
    Eur Urol Focus; 2019 Jan; 5(1):104-108. PubMed ID: 28753857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study.
    Necchi A; Anichini A; Raggi D; Briganti A; Massa S; Lucianò R; Colecchia M; Giannatempo P; Mortarini R; Bianchi M; Farè E; Monopoli F; Colombo R; Gallina A; Salonia A; Messina A; Ali SM; Madison R; Ross JS; Chung JH; Salvioni R; Mariani L; Montorsi F
    J Clin Oncol; 2018 Dec; 36(34):3353-3360. PubMed ID: 30343614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.